We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Flowserve (FLS) to Report Q1 Earnings: What's in the Offing?
Read MoreHide Full Article
Flowserve Corporation (FLS - Free Report) is scheduled to release first-quarter 2020 results on May 7, after market close.
The company surpassed estimates in each of the last four quarters, the positive earnings surprise being 8.34%, on average. Its fourth-quarter 2019 earnings of 66 cents per share surpassed the Zacks Consensus Estimate of 65 cents by 1.54%.
In the past three months, the company’s shares have lost 45.1% compared with the industry’s decline of 22.1%.
Factors at Play
Challenging conditions in the oil and gas end markets are expected to have adversely impacted bookings in the first quarter. Also, issues like commodity pricing, trade disruption and geopolitical uncertainties across the globe have caused delays in capital spending. These are likely to have hurt Flowserve's top-line performance.
Also, several of the company’s manufacturing facilities, global technology and engineering centers, quick response centers, and corporate headquarters have suffered temporary shutdowns, owing to the coronavirus outbreak. Notably, the impacts of the pandemic on its supply chain as well as the demand for its products and services along with the governmental regulations imposed in response to the crisis are anticipated to get reflected in Flowserve’s first-quarter results. Notably, the Zacks Consensus Estimate for first-quarter revenues from the company’s Flow Control Division segment is currently pegged at $273 million, indicating a decline of 3.2% from the year-ago reported figure.
Although Flowserve's realignment plan will benefit it in the long run, it has been increasing its expenses. We expect high restructuring costs to have affected the company’s first-quarter earnings. In addition, huge debt levels are likely to have negatively impacted Flowserve. Further, the company, which generates significant revenues from overseas operations, has been vulnerable to foreign exchange issues, which are expected to have affected both top and bottom-line performance in the first quarter.
However, the company’s investments in organic growth and other industrial opportunities as well as improved operating leverage are expected to have aided its profitability.
Earnings Whispers
According to our quantitative model, a stock needs to have the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or at least 3 (Hold) to increase the odds of an earnings beat. But that is not the case here as we will see below.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Flowserve has an Earnings ESP of +1.52%.
Axon Enterprise, Inc. currently has an Earnings ESP of +18.31% and a Zacks Rank #3.
Ball Corporation presently has an Earnings ESP of +1.56% and a Zacks Rank of 3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Flowserve (FLS) to Report Q1 Earnings: What's in the Offing?
Flowserve Corporation (FLS - Free Report) is scheduled to release first-quarter 2020 results on May 7, after market close.
The company surpassed estimates in each of the last four quarters, the positive earnings surprise being 8.34%, on average. Its fourth-quarter 2019 earnings of 66 cents per share surpassed the Zacks Consensus Estimate of 65 cents by 1.54%.
In the past three months, the company’s shares have lost 45.1% compared with the industry’s decline of 22.1%.
Factors at Play
Challenging conditions in the oil and gas end markets are expected to have adversely impacted bookings in the first quarter. Also, issues like commodity pricing, trade disruption and geopolitical uncertainties across the globe have caused delays in capital spending. These are likely to have hurt Flowserve's top-line performance.
Also, several of the company’s manufacturing facilities, global technology and engineering centers, quick response centers, and corporate headquarters have suffered temporary shutdowns, owing to the coronavirus outbreak. Notably, the impacts of the pandemic on its supply chain as well as the demand for its products and services along with the governmental regulations imposed in response to the crisis are anticipated to get reflected in Flowserve’s first-quarter results. Notably, the Zacks Consensus Estimate for first-quarter revenues from the company’s Flow Control Division segment is currently pegged at $273 million, indicating a decline of 3.2% from the year-ago reported figure.
Although Flowserve's realignment plan will benefit it in the long run, it has been increasing its expenses. We expect high restructuring costs to have affected the company’s first-quarter earnings. In addition, huge debt levels are likely to have negatively impacted Flowserve. Further, the company, which generates significant revenues from overseas operations, has been vulnerable to foreign exchange issues, which are expected to have affected both top and bottom-line performance in the first quarter.
However, the company’s investments in organic growth and other industrial opportunities as well as improved operating leverage are expected to have aided its profitability.
Earnings Whispers
According to our quantitative model, a stock needs to have the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or at least 3 (Hold) to increase the odds of an earnings beat. But that is not the case here as we will see below.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Flowserve has an Earnings ESP of +1.52%.
Flowserve Corporation Price and EPS Surprise
Flowserve Corporation price-eps-surprise | Flowserve Corporation Quote
Zacks Rank: Flowserve carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are some companies you may want to consider as our model shows that these have the right mix of elements to beat estimates this earnings season:
Intellicheck, Inc. (IDN - Free Report) has an Earnings ESP of +66.67% and a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Axon Enterprise, Inc. currently has an Earnings ESP of +18.31% and a Zacks Rank #3.
Ball Corporation presently has an Earnings ESP of +1.56% and a Zacks Rank of 3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>